Medidata’s Risk-Based Monitoring Solution Selected By Infinity Pharmaceuticals Inc. To Advance Oncology Research

NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Infinity Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the discovery, development and delivery of medicines for difficult-to-treat diseases, has expanded its use of the Medidata Clinical Cloud®. A long-standing Medidata customer, Infinity will now utilize Medidata’s best-in-class solution for risk-based monitoring (RBM)—a proven methodology for reducing trial costs while providing a higher level of data quality—in an upcoming Phase III oncology study for patients with indolent non-Hodgkin lymphoma.